Physician profile
Samuel Rosner
NPI 1114450871
$71,719.77
in general payments reported to CMS, 2019-2025
9 companies · $7,908 in 2025
The $7,908 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50K · 2023: $1,032 · 2024: $13K · 2025: $7,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $2,148 · Food and Beverage: $1,824 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,910.00 |
| Travel and Lodging | $2,147.93 |
| Food and Beverage | $1,824.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49,837.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12,810.49 | 2023-2025 | Tagrisso |
| Regeneron Pharmaceuticals, INC. | $5,174.38 | 2024 | Libtayo |
| Astrazeneca Uk Limited | $2,594.44 | 2024-2025 | Tagrisso |
| Merck Sharp & Dohme LLC | $1,000.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $187.65 | 2025 | Libtayo |
| Galvanize Therapeutics, INC | $87.95 | 2024 | Aliya System |
| Ge Healthcare | $27.40 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Rosner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.